Inhibition of CSRP2 Promotes Leukemia Cell Proliferation and Correlates with Relapse in Adults with Acute Myeloid Leukemia

Shujuan Wang1,*
Yu Zhang1,*
Yajun Liu2
Ruyue Zheng
Zhengen Wu
Yi Fan1
Mengya Li1
Menglin Li1
Tao Li1
Yafei Li1
Zhongxing Jiang1
Chong Wang1
Yanfang Liu1

1Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Department of Orthopaedics, Brown University, Warren Alpert Medical School/Rhode Island Hospital, Rhode Island, RI, USA

*These authors contributed equally to this work

Background: Relapse is a major obstacle in the treatment of acute myeloid leukemia (AML). Refinement of risk stratification may aid the identification of patients who are likely to relapse. Abnormal cysteine and glycine-rich protein 2 (CSRP2) has been implicated in various cancers, but its function remains unclear. The purpose of this study was to explore the role of CSRP2 in predicting adult AML recurrence.

Methods: RT-PCR was used to detect the expression of CSRP2 in 193 newly diagnosed adult AML patients and 44 healthy controls. The competitive risk model was used to calculate the cumulative incidence of relapse rate (CIR), Kaplan–Meier to calculate the relapse-free survival rate (RFS), and the Cox regression model to perform multivariate analysis. Viral transfection was used to construct AML cell lines with stable knockdown of CSRP2. CCK8 to detect proliferation and drug resistance, flow cytometry to detect cell cycle and apoptosis, and Western blot to detect key molecules in signaling pathways.

Results: CSRP2 transcript levels were higher in 193 adult AML compared with 44 healthy controls. In 149 patients who achieved complete remission, those with high CSRP2 transcript levels displayed a lower 2-year CIR and higher 2-year RFS, especially when receiving only chemotherapy. In multivariate analysis, a high CSRP2 transcript level was independently associated with a better RFS. Knockdown of CSRP2 promoted proliferation and cell cycle progression, and reduced chemosensitivity. Western blot analysis showed upregulation of p-AKT and p-CREB in CSRP2-knockdown AML cell lines. Inhibition assays suggested these two signaling pathways participated in the CSRP2-mediated proliferation effects in AML cell lines.

Conclusion: In summary, CSRP2 correlates with relapse in adult AML. Down-regulation of CSRP2 could promote the proliferation of AML cell lines by regulating the AKT and CREB signaling pathways. Therefore, CSRP2 may provide prognostic significance and potential therapeutic targets in the management of AML.

Keywords: acute myeloid leukemia, relapse, cysteine and glycine-rich protein 2, proliferation, cAMP-regulatory element-binding protein

Introduction

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults.1 Although the majority of patients with AML enter complete remission after induction chemotherapy, the recurrence rate is still high, which is the main factor affecting the long-term survival of patients.2 Transplantation may be an optional treatment, but it is challenging to identify high-risk patients suitable for early transplantation. Current risk stratification classifies patients according to age,
genetic mutations, and chromosomal changes. It is worth noting that many relapses occur in patients who present favorable characteristics at the time of initial diagnosis.\(^2,3\)

The new prognostic biomarkers may further improve the current risk stratification of adult AML, therefore optimizing treatment. There is an urgent need to improve the ability to identify patients with a high risk of recurrence, especially when they are currently stratified as patients with favorable risk. For these patients, intensive treatment may improve their prognosis.

Cysteine and glycine-rich protein 2 (CSRP2), which encodes the LIM domain protein CSR2P, participates in the regulatory process of organ development and cell differentiation.\(^4\) Studies show that CSRP2 is related to the dedifferentiation of hepatocellular carcinoma.\(^5\) As one of the components of the pseudopod actin bundle in breast cancer cells, it promotes the invasion and metastasis of breast cancer cells.\(^6,7\) Moreover, CSRP2 is a downstream target of miR-27a. Down-regulation of CSR2P can promote the proliferation and movement of gastric cancer cells.\(^8\) Our previous study suggests that CSRP2 is highly expressed in the blasts from patients with adult B cell acute lymphoblastic leukemia (B-ALL); and high expression of CSR2P is an independent adverse prognostic factor for normal karyotype adult B-ALL.\(^9\) To date, there is no study on the function and the prognostic relevance of CSR2P in adult AML patients. Here, we examined the levels of CSR2P transcripts for an association with relapse probability in adults with AML. We found that high CSR2P levels correlated with lower cumulative incidence of relapse and better relapse-free survival in adults with AML, especially for those who only received chemotherapy.

**Materials and Methods**

**Subjects**

Bone marrow samples were obtained from adults with AML (N=193) and normal individuals (N=44) recruited at the Department of Hematology of the First Affiliated Hospital of Zhengzhou University between February 2017 and June 2019. Complete clinical and laboratory data were available for 193 subjects. A total of 149 subjects achieved complete remission and were included in the relapse analysis. Subjects were followed until death, loss to follow-up or June 2020. Induction chemotherapy regimens include IA and DA regimens: standard-dose cytarabine (Ara-C) 100–200 mg·m\(^{-2}\)·d\(^{-1}\)×7 d combined with idarubicin 10–12 mg·m\(^{-2}\)·d\(^{-1}\)×3 d or daunorubicin (DNR) 60 mg·m\(^{-2}\)·d\(^{-1}\)×3 d. The treatment plan after remission is high-dose Ara-C (3g/m\(^{2}\) once every 12 h, 3d). Those who have not undergone hematopoietic stem cell transplantation (HSCT) share four courses; those who receive HSCT share two courses, followed by HSCT. In total, 41 subjects (28%) received an allogeneic HSCT. Complete remission (CR), relapse and risk-stratification were defined as previously described.\(^10\) Cumulative incidence of relapse (CIR) was determined from the date of first CR to the date of first relapse or death in complete remission. Relapse-free survival (RFS) was determined from the date of first CR to the date of first relapse. This study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University, and informed consent was obtained according to the Declaration of Helsinki.

**Cell Lines and Agents**

Human leukemia cell line HL60 was purchased from GeneChem (Shanghai, China, authenticated by STR profiling) and was cultured in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% FBS, 1% penicillin and streptomycin (all from Gibco, Billings, MT, USA) at 37°C with 5% CO\(_2\) in a humidified incubator. Small-molecular inhibitor KG501 was purchased from Sigma-Aldrich.

**Lentiviral Transduction**

HL60 cells were transfected with human CSR2P shRNA lentiviral particles or empty control lentiviral particles (GeneChem) at a multiplicity of infection (MOI) of 50. Medium containing lentiviral particles was replaced with complete medium 12 h post-infection. Stably transfected HL60 cells were selected with 2μM puromycin dihydrochloride (GeneChem) at 96 h post-infection. The efficiency of genetic modification for the inhibition of CSR2P was confirmed by both RT-qPCR and Western blot analysis.

**RNA Extraction, cDNA Preparation and RT-qPCR**

Mononuclear cells were isolated from bone marrow samples by density gradient centrifugation. RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA), and cDNA was synthesized as described.\(^11\) Gene transcript levels were determined according to the Taqman method.\(^12\) CSR2P transcript levels were normalized to ABL1 expression as recommended.
by the Europe Against Cancer group. Copy numbers of CSRP2 and ABL1 were calculated from standard curves using Ct values. Serial dilutions of plasmids expressing ABL1 and CSRP2 were amplified to construct standard quantification curves. Samples were assayed in duplicate to evaluate data reproducibility and average threshold Ct values calculated for expression analyses. Primers and probe sequences are as previously described.

Cell Proliferation and Viability Assay
Cell proliferation was analyzed by the Cell Counting Kit-8 (CCK8, Dojin Laboratories, Kumamoto, Japan) assay. A total of $1 \times 10^4$ cells in 100μL were seeded into each well of 96-well plates. 0, 24, 48 or 72 hours later 10 μL of the kit reagent was added to each well and 3 h later all plates were scanned by a microplate reader at 450 nm. The CCK8 test was also used to evaluate cell viability after drug exposure. Briefly, the cells were seeded at a density of $1 \times 10^5$ cells/mL, and daunorubicin (Solarbio) was added at concentrations of 62.5nM. After 24 h, 10 μL of the kit reagent was added to each well and 3 h later all plates were scanned according to the manufacturer’s instructions. All experiments were performed 3 times independently.

Analysis of Cell Cycle and Apoptosis
The cell cycle analysis was performed using a Cell Cycle Staining Kit (Beyotime Biotechnology, Shanghai, China), and cell apoptosis was assessed using an Annexin V/pro-pidium iodide (PI) apoptosis kit (Beyotime Biotechnology). The cells were starved in RPMI 1640 without FBS for 24 h for synchronization and then seeded at a density of $10^5$ cells/mL in six-well plates with complete medium. After 48 h, the cell cycle and apoptosis were determined by flow cytometry according to the manufacturer’s instructions.

Western Blot Analyses
Western blotting was performed as described previously. The primary antibodies used were rabbit anti-CSRP2 (Sigma, 1:500), rabbit anti-p21 (Cell Signaling Technology [CST], Beverly, MA, USA; 1:1000), rabbit anti-p27 (CST, 1:1000), rabbit anti-CDK4 (CST, 1:1000), rabbit anti-p-CREB (CST, 1:1000), rabbit anti-p-ERK (CST, 1:1000), rabbit anti p-P38 (CST, 1:1000), rabbit anti-p-SMAD3 (CST, 1:1000), rabbit anti p-AKT (CST, 1:1000), rabbit anti p53 (CST, 1:1000) and mouse anti-GAPDH (Solarbio, Beijing, China, 1:1000). The secondary antibody was goat anti-mouse IgG (Solarbio, 1:1000) and goat anti-rabbit IgG (Solarbio, 1:1000). The protein bands were determined using the ultra ECL kit (Biomed, Beijing, China) according to the manufacturer’s protocol.

Statistical Analyses
Clinical characteristics were compared between subjects with low and high transcript levels of CSRP2 using Pearson’s Chi-square analysis or Fisher exact test for categorical variables; Student’s t-test or Mann–Whitney U-test was used for continuous variables. Receiver operating characteristic (ROC) curves were constructed to evaluate the sensitivity and specificity of CSRP2 transcript levels to estimate RFS. Youden Index was used to calculate the optimal cutoff for high and low transcript levels. Survival functions were estimated by the Kaplan–Meier method and compared by the Log rank test. Cumulative incidences were estimated for relapse to accommodate competing risks. A Cox proportional hazard regression model was used to determine associations between CSRP2 transcript levels and RFS. Variables with $P<0.1$ in univariable analyses were entered into the multivariable analyses. $P<0.05$ was considered significant. Analyses were performed by SPSS software version 20.0 (Chicago, IL, USA), Graphpad Prism™ 5.01 (San Diego, California, USA) and R software package (version 3.5.0; http://www.r-project.org).

Results
CSRP2 is Highly Expressed in Bone Marrow Blasts from Subjects with Acute Myeloid Leukemia
To explore the role of CSRP2 in AML, we first examined CSRP2 levels in AML bone marrow blasts. Transcript levels of CSRP2 were higher in the AML subjects compared with healthy donors (median 3.76%, range [0–280.88%] vs 0.44% [0–1.78%]; $P=0.0001$; Figure 1A). According to French-America-British (FAB) classification of AML, subjects with FAB M0 and M2 subtypes had relatively higher transcript levels of CSRP2 compared with FAB M1, M4 and M5 subtypes (Figure 1B). Subjects with different cytogenetic risk stratifications also have different transcript levels of CSRP2. Low-risk subjects have significantly higher transcript levels of CSRP2 than high-risk subjects (20.09% [0.09%-280.88%] vs 2.15% [0.08%-177.86%]; $P=0.005$; Figure 1C).
**Figure 1** Transcript levels of CSRP2 in AML. (A) CSRP2 transcript levels in normal adults and adults with AML. Error bars indicate the median and upper and lower quartile values. (B) CSRP2 transcript levels in AML with different FAB subtypes. Error bars indicate the median values. *P<0.05* compared with M0; **P<0.01** compared with M0; ***P<0.05*** compared with M1; ****P<0.01*** compared with M1; &*P<0.05* compared with M2; &**P<0.001** compared with M2. (C) CSRP2 transcript levels in AML with different risk groups. Low, low-risk group; Medium, medium/intermediate group; High, high-risk group. Error bars indicate the median values.

CSRP2≥8.26% and <8.26% were defined as high transcript levels and low transcript levels, respectively. In the entire cohort, 39.4% (n = 76) patients had high CSRP2 transcript levels. Subjects with low CSRP2 transcript levels showed higher white blood cell (WBC) levels, higher platelets (PLT) levels and higher risk groups compared to subjects with high CSRP2 transcript levels (Table 1). Mutations in gene FLT3-ITD and NPM1 and CBFβ-

**Table 1** Association of CSRP2 Transcript Levels with the Clinical Characteristics of Adults with AML

<table>
<thead>
<tr>
<th>Variables</th>
<th>Total</th>
<th>L-CSRP2</th>
<th>H-CSRP2</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=193</td>
<td>N=117</td>
<td>N=76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>95 (49.2)</td>
<td>60 (51.3)</td>
<td>35 (47.4)</td>
<td>0.478</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>46 (14–87)</td>
<td>46 (14–81)</td>
<td>45 (14–87)</td>
<td>0.716</td>
</tr>
<tr>
<td>≥60, n (%)</td>
<td>36 (18.7)</td>
<td>23 (19.7)</td>
<td>13 (17.1)</td>
<td>0.656</td>
</tr>
<tr>
<td>WBC,×10^9/l</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M (R)</td>
<td>21.4 (1.0–367.9)</td>
<td>30.0 (1.1–367.9)</td>
<td>12.3 (1.0–258.2)</td>
<td>0.008</td>
</tr>
<tr>
<td>≥100, n (%)</td>
<td>32 (16.6)</td>
<td>23 (19.7)</td>
<td>9 (11.8)</td>
<td>0.154</td>
</tr>
<tr>
<td>Hb, g/l</td>
<td>81.0±21.2</td>
<td>81.4±20.5</td>
<td>80.4±22.3</td>
<td>0.736</td>
</tr>
<tr>
<td>PLT,×10^9/l</td>
<td>42 (4–414)</td>
<td>49 (5–414)</td>
<td>32 (4–215)</td>
<td>0.007</td>
</tr>
<tr>
<td>Risk group, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>48 (24.9)</td>
<td>21 (17.9)</td>
<td>27 (35.5)</td>
<td>0.002</td>
</tr>
<tr>
<td>Medium</td>
<td>69 (35.8)</td>
<td>39 (33.3)</td>
<td>30 (39.5)</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>76 (39.4)</td>
<td>57 (48.7)</td>
<td>19 (25.0)</td>
<td></td>
</tr>
<tr>
<td>Mutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLT3-ITD</td>
<td>38 (19.7)</td>
<td>33 (28.2)</td>
<td>5 (6.6)</td>
<td>0.000</td>
</tr>
<tr>
<td>NPM1</td>
<td>19 (9.8)</td>
<td>17 (14.5)</td>
<td>2 (2.6)</td>
<td></td>
</tr>
<tr>
<td>CEBPA</td>
<td>15 (7.8)</td>
<td>3 (2.6)</td>
<td>12 (15.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Karyotypes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBFβ</td>
<td>10 (5.2)</td>
<td>10 (8.5)</td>
<td>0 (0)</td>
<td>0.007</td>
</tr>
<tr>
<td>ETO</td>
<td>26 (13.5)</td>
<td>3 (2.6)</td>
<td>23 (30.3)</td>
<td>0.000</td>
</tr>
<tr>
<td>KMT2A</td>
<td>3 (1.6)</td>
<td>2 (1.7)</td>
<td>1 (1.3)</td>
<td>1.000</td>
</tr>
<tr>
<td>CR, n(%)</td>
<td>149 (77.2)</td>
<td>90 (76.9)</td>
<td>59 (77.6)</td>
<td>0.909</td>
</tr>
<tr>
<td>Transplant, n (%)</td>
<td>43 (22.3)</td>
<td>29 (24.8)</td>
<td>14 (18.4)</td>
<td>0.321</td>
</tr>
</tbody>
</table>

**Abbreviations:** AML, acute myeloid leukemia; H-CSRP2, high CSRP2 transcript level; L-CSRP2, low CSRP2 transcript level; R, Range; Hb, hemoglobin; PLT, platelets; WBC, white blood cell; CR, complete remission; CEBPA, biallelic mutated CEBPA; CBFβ, CBFβ-MYC111 or inv(16) (p13.1; q22) or t(16,16) (p13.1; q22); ETO, AML1-ETO or t(8;21)(q22; q22); KMT2A, KMT2A rearranged or t(v;11q23.3).
MYH11 fusion gene were more frequently found in subjects with low CSRP2 transcript levels. The biallelic mutation in gene CEBPA and AML1-ETO fusion gene were more frequently found in subjects with high CSRP2 transcript levels. There were no significant differences between CSRP2 transcript levels and other clinical features such as gender, age, hemoglobin level, CR rate and transplant (Table 1).

**CSRP2 Expression Levels are Independently Associated with Relapse in Subjects with AML**

To assess the clinical significance of CSRP2 in AML, we then analyzed the relation of CSRP2 levels in AML samples and the survival of these patients. Among the 193 subjects, 149 patients achieved CR and were used for CIR and RFS analysis. The median follow-up of these 149 patients was 460 days (range 73–1104 days). Among subjects with high and low CSRP2 transcript levels, the CR rates after one cycle of induction therapy did not differ significantly (77.6% vs 76.9%, P=0.909). The Kaplan–Meier analysis indicated that the cohorts (n = 90 patients) with low transcript levels of CSRP2 displayed a relatively lower 2-year RFS and worse 2-year CIR than the cohorts (n = 59 patients) with high transcript levels of CSRP2 (RFS: 45% [30–60%] vs 75% [58–92%], P=0.004; CIR: 51% [37–65%] vs 22% [7–37%], P=0.002; Figure 2A and B). In multivariate analysis, a high transcript level of CSRP2, a lower risk group and allo-HSCT were independently associated with a better RFS (Table 2). Other factors, such as gender, age and WBC count at diagnosis, did not show significant correlations with RFS (Table 2).

Because the prognosis of AML varied among individuals due to different post-remission therapies, we next analyzed the prognostic value of CSRP2 transcript levels in subjects receiving chemotherapy alone and those who underwent allo-HSCT. Our data indicated that in the 108 subjects who only received chemotherapy, low CSRP2 transcript levels were associated with a lower 2-year RFS and worse 2-year CIR than subjects with high CSRP2 transcript levels (RFS: 30% [12–48%] vs 71% [47–94%], P=0.001; CIR: 65% [47–83%] vs 25% [4–46%], P=0.001; Figure 2C and D). In multivariate analyses, low CSRP2 transcript levels were independently associated with a worse RFS (Table 2). Nevertheless, the above correlations were not statistically significant in 41 subjects receiving allo-HSCT post-CR (RFS: 77% [61–94%] vs 83% [62–100%], P=0.648; CIR: 22% [6–37%] vs 17% [0–39%], P=0.700; Figure 2E and F).

**CSRP2 Knockdown Promotes AML Cell Proliferation and Drug Resistance**

To explore the biological role of CSRP2 in AML, we constructed three stably transfected AML cell lines: the HL60-control cell line (CTRL), the HL60-knockdown cell line 1 (KD1) and the HL60-knockdown cell line 2 (KD2). The knockdown of CSRP2 was verified by RT-qPCR and Western blot (Figure 3A and B). The CCK-8 test showed that cell proliferation was significantly increased in both KD1 cells and KD2 cells compared to that in cells transfected with control lentiviral particles (Figure 3C).

Drug resistance is the primary reason for treatment-failure and relapse in AML. So we studied the relationship between CSRP2 and its sensitivity to daunorubicin. CSRP2 KD2 cells showed significantly increased proliferation, indicating more daunorubicin resistance compared with that of the control cells (Figure 3D).

**Knockdown of CSRP2 Promotes Cell Cycle Progression in AML Cells**

To elucidate how CSRP2 exhibits its antiproliferative effect on AML cells, we analyzed the role of CSRP2 in cell cycle progression and apoptosis. Flow cytometry results indicated that compared to the control group, knockdown of CSRP2 significantly decreased cell counts in the G0/G1 phase and increased cell counts in the G2/M phase (Figure 4A-C). Apoptosis analysis showed that knockdown of CSRP2 had no significant effect on total apoptosis in HL60 cells (Figure 4D-G). To further explore the effect of CSRP2 knockdown during the cell cycle, we assessed cell cycle-related proteins p21 and p27 by Western blot and found that both p21 and p27 were decreased while CDK4 showed no change (Figure 4H).

**Activation of p-AKT and p-CREB Pathways is Responsible for CSRP2-Mediated Proliferation in AML Cell Lines**

To understand the mechanisms behind the increased proliferation from CSRP2 down-regulation, we examined the changes in phosphorylation of leukemia cell growth-related proteins in HL60 cells. Levels of p-SMAD3 were largely unaffected, and phosphorylation of ERK and P38 were downregulated in CSRP2-KD cells (Figure 5A). Proliferation-related molecules, p-AKT and p-CREB,
were upregulated with CSRP2 knockdown (Figure 5A and B). The level of proapoptotic p53 was unaffected after CSRP2 knockdown (Figure 5A). To confirm the role of p-CREB in CSRP2-mediated effects, we used a p-CREB inhibitor KG-501 in CSPR2-KD1 cells. Both 25 µM and 50 µM KG-501 could significantly inhibit the expression of p-CREB and p-AKT (Figure 5C). Inhibition of p-CREB abolished the increased proliferation of CSRP2-KD1 and CSRP2-KD2 cells (Figure 5D and E). These data suggest that phosphorylation of CREB and AKT by downregulated expression of CSRP2 is responsible for the changes in the growth of CSRP2-knockdown HL60 cell lines.

**Discussion**

In this study, we evaluated the role of CSRP2 in predicting relapse of adult AML patients and explored its mechanism. The expression of CSRP2 in adult AML is...
Table 2 Univariate and Multivariate Analysis of RFS in the Whole Cohort and Chemotherapy Only

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>P-value</td>
<td>HR (95% CI)</td>
<td>P-value</td>
<td></td>
</tr>
<tr>
<td><strong>Whole cohort</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-CSRP2</td>
<td>0.37 (0.18–0.74)</td>
<td>0.005</td>
<td>0.42 (0.20–0.87)</td>
<td>0.020</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>0.91 (0.51–1.63)</td>
<td>0.752</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age ≥60 years</td>
<td>2.35 (1.20–4.64)</td>
<td>0.013</td>
<td>1.64 (0.81–3.32)</td>
<td>0.172</td>
<td></td>
</tr>
<tr>
<td>Risk group</td>
<td>0.006</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low vs High</td>
<td>0.28 (0.12–0.64)</td>
<td>0.003</td>
<td>0.43 (0.18–1.02)</td>
<td>0.056</td>
<td></td>
</tr>
<tr>
<td>Med vs High</td>
<td>0.51 (0.26–0.98)</td>
<td>0.042</td>
<td>0.66 (0.33–1.29)</td>
<td>0.221</td>
<td></td>
</tr>
<tr>
<td>WBC ≥100×10^9/l</td>
<td>1.48 (0.73–2.98)</td>
<td>0.278</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allo-HSCT</td>
<td>0.42 (0.19–0.89)</td>
<td>0.025</td>
<td>0.43 (0.19–0.94)</td>
<td>0.034</td>
<td></td>
</tr>
<tr>
<td><strong>Chemotherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-CSRP2</td>
<td>0.30 (0.14–0.65)</td>
<td>0.002</td>
<td>0.37 (0.16–0.84)</td>
<td>0.018</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.05 (0.55–1.99)</td>
<td>0.878</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age ≥60 years</td>
<td>2.03 (1.01–4.10)</td>
<td>0.048</td>
<td>1.67 (0.80–3.49)</td>
<td>0.177</td>
<td></td>
</tr>
<tr>
<td>Risk group</td>
<td>0.030</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low vs High</td>
<td>0.34 (0.14–0.79)</td>
<td>0.012</td>
<td>0.67 (0.26–1.73)</td>
<td>0.409</td>
<td></td>
</tr>
<tr>
<td>Med vs High</td>
<td>0.51 (0.24–1.08)</td>
<td>0.077</td>
<td>0.86 (0.37–1.99)</td>
<td>0.722</td>
<td></td>
</tr>
<tr>
<td>WBC ≥100×10^9/l</td>
<td>2.88 (1.38–5.99)</td>
<td>0.005</td>
<td>1.79 (0.78–4.08)</td>
<td>0.167</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; HR, hazard ratio; RFS, relapse-free survival; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; H-CSRP2, high CSRP2 transcript level; WBC, white blood cell.

significantly higher than that of normal controls, while the low expression of CSRP2 is an independent adverse prognostic factor for relapse in adult AML patients. Knockdown of CSRP2 can promote AML cell line proliferation and cell cycle progression, and increase drug resistance. This effect may be carried out through the AKT and CREB signaling pathway.

It has been found that CSRP2 is abnormally expressed in several tumors, but its role remains controversial. For example, high expression of CSRP2 was significantly associated with the risk of metastasis in patients with breast cancer and poor prognosis in adult B-ALL patients with normal karyotype. However, CSRP2 downregulation increases the proliferation and motility of gastric cancer cells. In this study, we found that higher CSRP2 expression in AML was associated with relatively better RFS and lower CIR. The different role of CSRP2 in malignant diseases may partly contribute to the companying mutations of other genes. For example, CSRP2 high expression was seen in patients with KMT2A rearrangement, a poor prognosis BCP ALL subtype. In contrary, AML cases with low CSRP2 transcript levels are more frequent companied by mutations in gene FLT3-ITD, which may contribute to the adverse outcomes. The genetic alterations correlate with differential expression levels of CSRP2 and may explain the poor outcome related to low CSRP2. In addition, the prognosis of AML varies according to the treatment after remission, we further analyzed the prognostic significance of CSRP2 in subjects who received only chemotherapy and those who received allo-HSCT. It is worth noting that the above correlation between the level of CSRP2 transcription and RFS and CIR can still be detected in subjects receiving chemotherapy only, while the prognosis of patients receiving allo-HSCT was not affected by the expression level of CSRP2. Because the prognostic factors of AML are complicated, we performed a multivariate analysis to resolve this complexity. In particular, the low transcription level of CSRP2 at the time of diagnosis was an independent adverse risk factor for relapse in adults with AML, especially for patients who received chemotherapy alone. These data suggest that CSRP2 can be a potential target for predicting the recurrence of AML patients, especially for patients who only receive chemotherapy after CR.

CSRP2 participates in multiple processes both inside and outside of the cells through interactions with a diverse set of cellular targets. Hoffmann et al identified CSRP2 as a new cytoskeletal component of invadopodia that critically promoted breast cancer cell invasion and metastasis. Wang et al reported that CSRP2 was a downstream target of miR-27a in gastric cells by luciferase-reporter assay. They further investigated the role of

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 03-Jul-2021
For personal use only.
OncoTargets and Therapy 2020:13 12555
submit your manuscript | www.dovepress.com DovePress
CSRP2 in gastric cancer. They tested the proliferation and motility of HSF-1 cells by downregulation of CSRP2 expression. They found that the downregulation of CSRP2 increased the proliferation and motility of gastric cancer cells.\(^8\) Our previous study showed that CSRP2 promoted proliferation in B-ALL cell lines.\(^9\) However, the data in this study indicated that knockdown of CSRP2 promotes proliferation and cell cycle progression as well as drug resistance in AML cell lines. It might reflect various functions of CSRP2 in different types of cancers.

We also studied changes in several growth- and survival-related pathways in association with CSRP2 downregulation in HL60 cells. The phosphoinositide 3-kinase (PI3K)-Akt pathway (PI3K-Akt pathway) is among one of the intracellular pathways aberrantly upregulated in cancers including AML.\(^17\) Activation of this pathway seems important in leukemogenesis. Given the central role of this pathway in metabolism, the bioenergetics of AML cells may depend on downstream signaling within this pathway.\(^17\) Our results showed an upregulation of AKT phosphorylation in CSRP2 knockdown leukemia cells, suggesting an involvement of p-AKT in pro-survival mechanisms mediated by CSRP2. Transcription factors are key regulators of the gene expression pattern and directly control central processes such as proliferation, survival and self-renewal.\(^18\) cAMP-regulatory element-binding protein (CREB) is a crucial transcriptional factor, which can be activated through phosphorylation by a number of kinases, including Akt.\(^18\) CREB is over-expressed and constitutively phosphorylated in a number of human cancer including AML, and appears to play a direct role in disease pathogenesis and prognosis.\(^18\) We found that both p-AKT and p-CREB levels were

---

**Figure 3** Inhibition of CSRP2 promoted the proliferation and drug resistance of AML cells. (A-B) The efficiency of CSRP2 knockdown in the HL60 cell line was verified by (A) quantitative real-time polymerase chain reaction and (B) Western blotting, respectively. \(^**\)P<0.01 compared with CTRL cells. (C) Cell proliferation was detected by the CCK-8 assay in HL60 CSRP2-KD and CTRL cells. \(^**\)P<0.01 compared with CTRL cells; \(^***\)P<0.001 compared with CTRL cells. (D) Knockdown of CSRP2 decreased sensitivity to daunorubicin in HL60 cells; \(^*\)P<0.05 compared with CTRL cells. Error bars indicate the standard deviation.

**Abbreviations:** CTRL, control; KD, knockdown.
increased in CSRP2 knockdown leukemia cells, indicating that CSRP2 knockdown may increase p-CREB levels through upregulation of p-AKT. Several cell cycle-related genes are regulated by p-CREB and p-AKT. Knockdown of CREB induces cell cycle arrest and significantly reduces tumor cell proliferation. Our research found that cyclin-dependent kinase inhibitors p21 and p27 were reduced in CSRP2 knockdown cells. These results indicate that p-CREB and p-AKT may influence proliferation by regulating the expression of cell cycle-related genes. Interestingly, a CREB inhibitor KG501 reduced both p-CREB and p-AKT levels and ameliorated pro-proliferative effects caused by knockdown of CSRP2. These data suggested that CSRP2 could modulate the growth and survival of AML leukemia cells through the regulation of AKT and CREB.

Figure 4 Cell cycle and cell apoptosis analysis in HL60 CSRP2-KD cells. (A–C) Propidium iodide (PI) staining was used to analyze the cell cycle of HL60 CSRP2-KD cells compared to those of their vector controls. (D–G) Apoptosis of HL60 CSRP2-KD cells compared to that of their vector controls. CTRL, control; KD, knockdown; ns, the difference is not statistically significant. Error bars indicate the standard deviation. *P<0.05 compared with CTRL cells. (H) Alterations in a cell cycle-related protein assay in HL60 CSRP2-KD cells compared to those of their vector controls.
pathways. In this regard, these abnormal alterations caused by CSRP2 may provide potential therapeutic drug targets in the future. We also observed decreases in the phosphorylation of p38 MAPK and p-ERK in CSRP2-KD leukemia cells. They may be downstream effectors modulated by CSRP2 in leukemia cells, which will require further investigation in the future. Maybe higher pAKT sustains higher proliferation without implying pERK in the pathway. The role of p38 MAPK is more difficult to interpret as it has pro-apoptotic and oncogenic functions depending on cellular context and stimuli. The role of p38 MAPK pathway in CSRP2-KD leukemia cells will require further investigation in the future.

There are several limitations to our study. First, it was retrospective and lack of an external validation cohort.
Second, patients were not randomized to receive HSCT or chemotherapy due to practical and ethical reasons. Third, there is interaction between CSRP2 transcript levels and risk stratification, gene mutations and karyotypes. Considering these limitations, our conclusions require a randomized, prospective trial in a larger population group to provide more objective results.

In summary, our data indicated that low CSRP2 transcript levels were correlated with a relatively higher CIR and worse RFS in adults with AML, especially for those who received only chemotherapy. In addition, knockdown of CSRP2 promoted proliferation and cell cycle progression of AML cell lines through regulation of the AKT and CREB pathways. Taken together, although further confirmation is needed, our data suggest that CSRP2 may provide prognostic significance and potential therapeutic targets in the management of AML.

**Data Sharing Statement**

All raw data are accessible by requesting the corresponding author (Yanfang Liu).

**Acknowledgments**

We thank all the treating physicians for allowing us to enroll their patients and the patients for allowing us to analyze their data.

**Author Contributions**

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Funding**

This work was supported by the National Natural Science Foundation of China [grant number 81800137 and U1804191] and Henan Medical Science and Technology Research Project (grant number 2018020068).

**Disclosure**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**References**